Understanding Your Diagnosis: C9ORF72 HD-Like Syndrome
At a Glance
A C9ORF72 repeat expansion can cause Huntington disease-like movement, mood, and cognitive symptoms after a negative HTT test. It is also linked to ALS and frontotemporal dementia, but variable expressivity means people do not necessarily develop every condition.
For many people with Huntington’s-like symptoms, the journey to a diagnosis is a long and exhausting process often called a diagnostic odyssey [1]. You may have spent years visiting different specialists, undergoing repeated testing, and perhaps even feeling that your symptoms were being dismissed because the standard tests were coming back negative [2].
If you were tested for Huntington’s disease and the result for the HTT gene was negative, but your symptoms—such as involuntary movements, mood changes, or cognitive shifts—continued to progress, doctors may describe your condition as an HD phenocopy [3]. An HD phenocopy is a clinical description, not a final diagnosis; it means a condition that looks and acts like a specific disease (in this case, Huntington’s) but is caused by a different genetic or environmental factor [4].
Receiving a diagnosis of a C9ORF72 expansion can be both validating and overwhelming. It provides an answer to the “why” behind your symptoms, but it also places you within a complex biological spectrum that links three seemingly different diseases [5].
The Rarity of the C9ORF72 HD-Like Variant
The C9ORF72 expansion is a rare cause of Huntington’s-like symptoms. While Huntington’s disease itself is well-known, this specific variant is found in only about 1% to 2% of people in specific research cohorts who have HD-like symptoms but test negative for the HTT mutation [6][7]. This estimate varies depending on the referral population, ancestry, and testing methods.
Because it is so rare, many healthcare providers may not have encountered it before. This rarity can add to the feeling of isolation for families, as the resources and support groups built for classic Huntington’s may not always feel like a perfect fit for your specific biological reality [8].
One Gene, Three Diseases
The most unique—and sometimes frightening—aspect of the C9ORF72 expansion is its biological link to two other major neurological conditions: Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) [5].
Biologically, the expansion in this gene creates abnormal RNA and proteins in the brain and spinal cord [9][10]. Depending on which part of the nervous system is most affected, the same genetic expansion can show up in different ways:
- Movement focus: If the expansion primarily affects the basal ganglia (the brain’s movement control center), it looks like Huntington’s disease, causing chorea (involuntary, jerky movements) or parkinsonism [11][12].
- Cognitive and Behavioral focus: If it affects the frontal and temporal lobes of the brain, it can lead to Frontotemporal Dementia (FTD), involving significant personality changes, loss of empathy, or language difficulties [13].
- Motor Neuron focus: If it affects the motor neurons that control muscles, it leads to ALS (Lou Gehrig’s disease), causing muscle weakness, wasting, and twitching [14].
Understanding Your Specific Path
It is important to understand that having this expansion does not mean you will definitely develop every symptom of ALS or FTD. This is due to variable expressivity, which means the same genetic change can act differently in different people [15].
However, your care team may monitor you for “clues” that aren’t typical for classic Huntington’s. These might include:
- Early psychiatric symptoms: Some case reports suggest patients may experience significant behavioral changes or psychosis, though it is not certain these are more common than in classic HD [11].
- Motor neuron signs: Doctors may check for muscle wasting (atrophy) or small muscle twitches (fasciculations) that are characteristic of the ALS side of the spectrum [14].
- Seizures: While rare in classic HD, seizures are occasionally reported in the wider C9ORF72 spectrum, though they are neither required nor diagnostic [11].
Navigating the Emotional Impact
The transition from thinking you had Huntington’s to learning you have a C9ORF72 expansion can be a significant emotional pivot. Some people feel a sense of relief at finally having an answer, while others feel grief, anxiety, or confusion when this new result arrives [16].
This diagnosis also changes the conversation for your family. Unlike classic Huntington’s, where children are at risk for the same disease, a family member of someone with a C9ORF72 expansion might be at risk for a different condition in the spectrum, such as ALS or FTD [15]. Working with a genetic counselor who is familiar with the C9ORF72 spectrum is essential for helping your relatives understand their own risks and testing options [17].
Though your biological “address” has changed, the need for compassionate, multidisciplinary care—including physical therapy, speech therapy, and psychological support—remains the same [18].
Common questions in this guide
What does a C9ORF72 expansion mean after a negative Huntington disease test?
Does having a C9ORF72 expansion mean I will develop ALS or frontotemporal dementia?
What symptoms may doctors monitor with C9ORF72-related disease?
Could my relatives be at risk if I have a C9ORF72 expansion?
What care may be helpful after a C9ORF72 diagnosis?
Why can it take so long to diagnose C9ORF72 HD-like syndrome?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
About the terminology
What does it mean to be described as an HD phenocopy?
Rarity and support
How rare is the C9ORF72 variant, and are there support groups that fit it?
Family and genetic counseling
What should my family know about their own risks, and would a genetic counselor help?
Get notified when new evidence is published on Huntington disease-like syndrome due to C9ORF72 expansions.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Whole-exome sequencing in adult patients with developmental and epileptic encephalopathy: It is never too late.
Minardi R, Licchetta L, Baroni MC, et al.
Clinical genetics 2020; (98(5)):477-485 doi:10.1111/cge.13823.
PMID: 32725632 - 2
Diagnostic odyssey of Guillain-Barré syndrome in children.
Kobayashi Takahashi Y, Hayakawa I, Abe Y
Brain & development 2024; (46(2)):108-113 doi:10.1016/j.braindev.2023.10.004.
PMID: 37914621 - 3
Non-Huntington's disease chorea: an expanding universe with acquired causes.
Cardoso F, Maia D, Maciel R, et al.
Brain : a journal of neurology 2026; (149(6)):1860-1873 doi:10.1093/brain/awag038.
PMID: 41612618 - 4
Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic Approach.
Mariani LL, Tesson C, Charles P, et al.
JAMA neurology 2016; (73(9)):1105-14 doi:10.1001/jamaneurol.2016.2215.
PMID: 27400454 - 5
Expanding the spectrum of C9ORF72-related neurodegenerative disorders in the Greek population.
Kartanou C, Kontogeorgiou Z, Rentzos M, et al.
Journal of the neurological sciences 2022; (442()):120450 doi:10.1016/j.jns.2022.120450.
PMID: 36252286 - 6
Screening for the C9ORF72 expansion in Greek Huntington Disease phenocopies and controls and meta-analysis of current data.
Rikos D, Marogianni C, Provatas A, et al.
Tremor and other hyperkinetic movements (New York, N.Y.) 2020; (10()):5 doi:10.5334/tohm.61.
PMID: 32775019 - 7
C9orf72 Hexanucleotide Repeat in Huntington-Like Patients: Systematic Review and Meta-Analysis.
Alva-Diaz C, Alarcon-Ruiz CA, Pacheco-Barrios K, et al.
Frontiers in genetics 2020; (11()):551780 doi:10.3389/fgene.2020.551780.
PMID: 33240313 - 8
Ultra-rare ultra-care: Assessing the impact of caring for children with ultra rare diseases.
Domaradzki J, Walkowiak D
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2024; (48()):78-84 doi:10.1016/j.ejpn.2023.12.003.
PMID: 38071849 - 9
Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions.
Todd TW, Petrucelli L
Journal of neurochemistry 2016; (138 Suppl 1()):145-62 doi:10.1111/jnc.13623.
PMID: 27016280 - 10
Blocking RAN translation without altering repeat RNAs rescues C9ORF72-related ALS and FTD phenotypes.
Jiang X, Schaeffer L, Patni D, et al.
Science (New York, N.Y.) 2026; (391(6785)):eadv2600 doi:10.1126/science.adv2600.
PMID: 41643021 - 11
C9orf72 and its Relevance in Parkinsonism and Movement Disorders: A Comprehensive Review of the Literature.
Bourinaris T, Houlden H
Movement disorders clinical practice 2018; (5(6)):575-585 doi:10.1002/mdc3.12677.
PMID: 30637277 - 12
Hereditary chorea - what else to consider when the Huntington's disease genetics test is negative?
Malek N, Newman EJ
Acta neurologica Scandinavica 2017; (135(1)):25-33 doi:10.1111/ane.12609.
PMID: 27150574 - 13
Revisiting the neuropsychiatry of Huntington's disease.
Teixeira AL, de Souza LC, Rocha NP, et al.
Dementia & neuropsychologia 2016; (10(4)):261-266 doi:10.1590/s1980-5764-2016dn1004002.
PMID: 29213467 - 14
Concurrent Amyotrophic Lateral Sclerosis and Huntington's Disease.
Takahashi R, Furuta M, Nagashima K, Ikeda Y
Internal medicine (Tokyo, Japan) 2025; (64(2)):297-300 doi:10.2169/internalmedicine.3232-23.
PMID: 38897956 - 15
Who and Why? Requests for Presymptomatic Genetic Testing for Amyotrophic Lateral Sclerosis/Frontotemporal Dementia vs Huntington Disease.
Amador MDM, Gargiulo M, Boucher C, et al.
Neurology. Genetics 2021; (7(1)):e538 doi:10.1212/NXG.0000000000000538.
PMID: 33376800 - 16
Lessons learned from 30 years of presymptomatic testing in Huntington Disease.
Pierron L, Hébert M, Gargiulo M, Durr A
Revue neurologique 2025; (181(9)):852-862 doi:10.1016/j.neurol.2025.07.009.
PMID: 41238315 - 17
Current knowledge of Huntington's disease-like 2 genetic testing, clinical presentation, and patient experiences: A systematic review.
Hoffmann K, White S, Sexton A
Journal of Huntington's disease 2026; (15(3)):293-316 doi:10.1177/18796397251411109.
PMID: 41564273 - 18
Predictive testing for neurodegenerative diseases in the age of next-generation sequencing.
Goldman J, Xie S, Green D, et al.
Journal of genetic counseling 2020; doi:10.1002/jgc4.1342.
PMID: 33090625
This page is for informational purposes only and is not medical advice; it cannot diagnose you or predict whether ALS or FTD will develop. Discuss your C9ORF72 results and family-testing options with your neurologist and genetic counselor.